Natco Pharma Surges After Receiving Tentative FDA Nod for Olaparib Tablets, Boosting Market Outlook

Natco Pharma Surges After Receiving Tentative FDA Nod for Olaparib Tablets, Boosting Market Outlook​

Natco Pharma shares experienced a significant upward movement after announcing that it has received tentative approval from the U.S. Food and Drug Administration (U.S. FDA). The stock saw gains of up to 4.5% on Monday, touching an intraday high of Rs 987.55 on the NSE. This news centers around the company's generic version of Olaparib Tablets.

Decoded: Significance of U.S. FDA Tentative Approval​

The pharmaceutical firm informed exchanges that the U.S. FDA granted tentative approval for Olaparib Tablets in both 100 mg and 150 mg strengths. These tablets are bioequivalent to AstraZeneca's drug, Lynparza. The scope of this approval covers the indications specified in the reference-listed drug's approved labelling.

Natco Pharma will undertake the manufacturing of these Olaparib tablets. Its marketing partner for the U.S. market is Alembic Pharmaceuticals Ltd., who will be responsible for commercialization and distribution. Management also noted that the Para IV patent litigation pertaining to the product remains an ongoing matter. Industry sales estimates indicate that Olaparib tablets could generate approximately $1.4 billion in U.S. sales over 12 months ended March 2026, underscoring the substantial market opportunity awaiting final approval and dispute resolution.

Strategic International Expansion and Acquisitions​

The positive regulatory news arrives following a recent strategic move by Natco Pharma to expand its international footprint. On July 14, the company completed the acquisition of an additional 13.25% stake in Adcock Ingram Holdings Proprietary Limited.

This transaction was executed through the wholly-owned subsidiary, Natco Pharma South Africa Proprietary Limited. This move increased Natco's total stake in Adcock Ingram from 35.75% to 49%. The acquisition was completed for an aggregate consideration of around ZAR 1.81 billion, which equates approximately to Rs 1,060 crore.

Stock Valuation and Financial Snapshot Analysis​

The stock performance reflected the market reaction to the FDA update. Natco Pharma touched a high of Rs 987.55 on Monday. While there were gains, the stock currently trades well below its 52-week high of Rs 1,226.80, and its 52-week low is registered at Rs 789.

The company commands a market capitalization of approximately Rs 16,925 crore. Valuation metrics remain relatively modest compared to many pharmaceutical peers. Natco Pharma is currently trading at a price-to-earnings (P/E) ratio of 11.93 and a price-to-book (P/B) ratio of 1.83.

Technical Outlook and Shareholding Trends​

On technical charts, the stock's 14-day Relative Strength Index (RSI) stands at 47.6, suggesting neutral momentum in the short term. An RSI reading below 30 signifies an oversold condition, while above 70 indicates overbought conditions.

Regarding trend indicators, the stock is trading beneath four of its eight key simple moving averages (SMAs). However, it continues to remain above its long-term 150-day and 200-day SMAs, a pattern that reflects resilience in the broader market trend despite recent near-term weakness.

Institutional shareholding data for the June 2026 quarter showed mixed activity among investors. Foreign Institutional Investors (FIIs) reduced their holding to 16.99% from 17.37% in the previous quarter. Conversely, Mutual Funds increased their holdings up to 1.92% from 1.72%, signaling selective domestic institutional buying.